This is a prospective, randomized and controlled clinical trial of photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSC). The patients who met the inclusion criteria were randomly divided into 50% dose PDT treatment group and 70% dose PDT treatment group. The primary treatment success rate and adverse event rate of the two groups were compared by optical coherence tomography (OCT), and then the best PDT treatment scheme for chronic CSC was summarized.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
100
Verteporfin (Visudyne; Novartis, Switzerland) was administrated intravenously over 10 minutes with 50% doses based on the randomization . Fifteen minutes after commencing the verteporfin infusion, a contact lens (Volk® area centralis) was positioned on the affected eye, the treatment area was exposed to a 689 nm laser with a fluence of 600 mw/cm2 for 83 seconds and a total laser energy of 50 J/cm2.
Verteporfin (Visudyne; Novartis, Switzerland) was administrated intravenously over 10 minutes with 70% doses based on the randomization . Fifteen minutes after commencing the verteporfin infusion, a contact lens (Volk® area centralis) was positioned on the affected eye, the treatment area was exposed to a 689 nm laser with a fluence of 600 mw/cm2 for 83 seconds and a total laser energy of 50 J/cm2.
Peking University People's Hospital
Beijing, Beijing Municipality, China
RECRUITINGThe complete absorption rate of subretinal fluid
The absorption of subretinal fluid was observed on optical coherence tomography at each follow up visit
Time frame: 3 months after the primary PDT
Central foveal thickness change after the PDT
The hight of central foveal thickness was measured on optical coherence tomography at each visit
Time frame: 12 months after the PDT
Subfoveal choroidal thickness change after the PDT
The hight of Subfoveal choroidal thickness was measured on optical coherence tomography at each visit
Time frame: 12 months after the PDT
Best corrected visual acuity change after the PDT
The BCVA was tested at each visit
Time frame: 12 months after the PDT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.